International consensus guidance for management of myasthenia gravis

Guideline Myasthenia Gravis 2016.pdf

Unduh PDF • 253KB

Acquired myasthenia gravis (MG) is a disorder of neuromuscular transmission, resulting from binding of autoantibodies to components of the neuromuscular junction, most commonly the acetylcholine receptor (AChR). The incidence ranges from 0.3 to 2.8 per 100,000,1 and it is estimated to affect more than 700,000 people worldwide. The increasing use of immunomodulating therapies has been a major factor in improving the prognosis for patients with MG in recent years.2 The various treatment options must be weighed in the context of individual patient factors.